This phase 2 trial demonstrates that memantine, an NMDA receptor antagonist, significantly reduces premature atrial contractions (PACs) and nonsustained atrial tachycardia burden, suggesting the cardiac glutamatergic system as a novel therapeutic target for atrial arrhythmias.